Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD To Its Board Of Directors
1/15/2014 8:00:19 AM
OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --
Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.
Help employers find you! Check out all the jobs and post your resume.